AU2003239038B2 - New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof - Google Patents

New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof Download PDF

Info

Publication number
AU2003239038B2
AU2003239038B2 AU2003239038A AU2003239038A AU2003239038B2 AU 2003239038 B2 AU2003239038 B2 AU 2003239038B2 AU 2003239038 A AU2003239038 A AU 2003239038A AU 2003239038 A AU2003239038 A AU 2003239038A AU 2003239038 B2 AU2003239038 B2 AU 2003239038B2
Authority
AU
Australia
Prior art keywords
around
compound
sexual
dysfunction
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003239038A
Other languages
English (en)
Other versions
AU2003239038A1 (en
Inventor
Nils-Olof Lindberg
Katarina Lindell
Alice C. Martino
Kristina Thyresson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McNeil AB
Original Assignee
McNeil AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McNeil AB filed Critical McNeil AB
Publication of AU2003239038A1 publication Critical patent/AU2003239038A1/en
Assigned to PFIZER CONSUMER HEALTHCARE HEALTH AB reassignment PFIZER CONSUMER HEALTHCARE HEALTH AB Request for Assignment Assignors: PFIZER HEALTH AB
Assigned to MCNEIL AB reassignment MCNEIL AB Request for Assignment Assignors: PFIZER CONSUMER HEALTHCARE HEALTH AB
Application granted granted Critical
Publication of AU2003239038B2 publication Critical patent/AU2003239038B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Confectionery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003239038A 2002-08-05 2003-06-18 New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof Ceased AU2003239038B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0202365A SE0202365D0 (sv) 2002-08-05 2002-08-05 New formulation and use thereof
SE0202365-3 2002-08-05
PCT/SE2003/001022 WO2004012702A1 (en) 2002-08-05 2003-06-18 New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof

Publications (2)

Publication Number Publication Date
AU2003239038A1 AU2003239038A1 (en) 2004-02-23
AU2003239038B2 true AU2003239038B2 (en) 2008-01-03

Family

ID=20288677

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003239038A Ceased AU2003239038B2 (en) 2002-08-05 2003-06-18 New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof

Country Status (15)

Country Link
EP (1) EP1539096A1 (sv)
JP (1) JP2005539008A (sv)
CN (1) CN1674866B (sv)
AR (1) AR040797A1 (sv)
AU (1) AU2003239038B2 (sv)
BR (1) BR0313224A (sv)
CA (1) CA2495527C (sv)
IL (1) IL166031A0 (sv)
MX (1) MXPA05000978A (sv)
NZ (1) NZ537520A (sv)
RU (1) RU2312665C2 (sv)
SE (1) SE0202365D0 (sv)
TW (1) TW200418470A (sv)
WO (1) WO2004012702A1 (sv)
ZA (1) ZA200500051B (sv)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
GB0509317D0 (en) * 2005-05-06 2005-06-15 Clarke Anthony Pharmaceutical formulation of apomorphine
DE102010024866A1 (de) * 2010-06-24 2011-12-29 Pharmatech Gmbh Formulierung zur Geschmacksmaskierung
EP3299010B1 (de) 2016-09-21 2022-11-09 LTS Lohmann Therapie-Systeme AG Orale darreichungsform
EP3758675A1 (de) 2018-03-01 2021-01-06 LTS Lohmann Therapie-Systeme AG Orale darreichungsform mit theobrominfreiem kakao

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002041840A2 (en) * 2000-11-16 2002-05-30 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755180A (en) * 1986-06-16 1988-07-05 Alza Corporation Dosage form comprising solubility regulating member
FR2717387B1 (fr) * 1994-03-17 1996-10-18 Hi Pharmtech Procédé de fabrication de comprimés à croquer à base de troxérutine, de carbonate de calcium, de phosphate de calcium, d'aspartate d'arginine, de glutamate d'arginine d'amoxicilline.
US6121276A (en) 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
ES2105970B1 (es) * 1995-08-02 1998-07-01 S A L V A T Lab Sa Composicion farmaceutica oral de ciprofloxacino, no acuosa, estable y con caracteristicas organolepticas mejoradas.
CA2178021C (en) * 1996-04-19 1999-09-28 Theodore H. Stanley Tobacco substitute
DE69721559T2 (de) * 1997-01-06 2003-11-27 Pfizer Geschmacksmaskierte pharmazeutische dosisform mit schneller freisetzung
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
JP2000095710A (ja) * 1998-09-21 2000-04-04 Taisho Pharmaceut Co Ltd カカオ末を配合した経口用固形製剤
JP2000119198A (ja) * 1998-10-16 2000-04-25 Eisai Co Ltd 苦味等の隠蔽されたホスフォジエステラーゼ阻害剤含有経口製剤
US6060094A (en) * 1998-10-30 2000-05-09 Nestec S.A. Method of reducing fat in fat-based coating for confectionery products
SE9803986D0 (sv) * 1998-11-23 1998-11-23 Pharmacia & Upjohn Ab New compositions
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US6291471B1 (en) 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
CA2378257A1 (en) 1999-08-10 2001-02-15 William E. Sponsel Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight
JP2001114668A (ja) * 1999-10-13 2001-04-24 Meiji Seika Kaisha Ltd チョコレート剤
AU2440901A (en) 1999-12-30 2001-07-16 Tap Holdings, Inc. Oral mucosal dosage forms of apomorphine
WO2002005820A1 (en) * 2000-07-19 2002-01-24 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
JP2002193839A (ja) * 2000-12-27 2002-07-10 Meiji Seika Kaisha Ltd ココア製剤
JP2004520389A (ja) * 2001-02-08 2004-07-08 ファルマシア・コーポレーション 性的不全の治療のための早期効果発現薬剤
US20020172732A1 (en) * 2001-03-21 2002-11-21 Wies Ter Laak Composition comprising cocoa

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002041840A2 (en) * 2000-11-16 2002-05-30 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same

Also Published As

Publication number Publication date
NZ537520A (en) 2006-11-30
IL166031A0 (en) 2006-01-15
MXPA05000978A (es) 2005-12-12
CA2495527C (en) 2008-12-30
RU2005102835A (ru) 2005-08-10
RU2312665C2 (ru) 2007-12-20
AU2003239038A1 (en) 2004-02-23
BR0313224A (pt) 2005-07-05
TW200418470A (en) 2004-10-01
JP2005539008A (ja) 2005-12-22
CA2495527A1 (en) 2004-02-12
EP1539096A1 (en) 2005-06-15
ZA200500051B (en) 2006-12-27
CN1674866A (zh) 2005-09-28
WO2004012702A1 (en) 2004-02-12
AR040797A1 (es) 2005-04-20
CN1674866B (zh) 2012-09-26
SE0202365D0 (sv) 2002-08-05

Similar Documents

Publication Publication Date Title
US20100069397A1 (en) Sexual dysfunction compounds
US20110288132A1 (en) Nicotine and Cocoa Powder Compositions
CA2461517C (en) Nicotine formulations comprising cocoa and use thereof
AU2002334522A1 (en) New formulations and use thereof
ZA200507719B (en) Formulations comprising an active ingredient and cocoa powder and use thereof
US20100197742A1 (en) New formulations and use thereof
AU2003239038B2 (en) New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof
ZA200506710B (en) Formulations comprising tolterodine and cocoa powder and use thereof
KR20050047527A (ko) 코코아 분말을 포함하는, 신속하게 발현되는 신규성적-기능장애-화합물-함유 제약 제제 및 그의 용도
US20040191345A1 (en) New formulations and use thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: PFIZER CONSUMER HEALTHCARE HEALTH AB

Free format text: FORMER APPLICANT(S): PFIZER HEALTH AB

TC Change of applicant's name (sec. 104)

Owner name: MCNEIL AB

Free format text: FORMER NAME: PFIZER CONSUMER HEALTHCARE HEALTH AB

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired